{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:31:09Z","timestamp":1790771469825,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T00:00:00Z","timestamp":1561334400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T00:00:00Z","timestamp":1561334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-019-1931-x","type":"journal-article","created":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T10:39:40Z","timestamp":1561372780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Antibodies against specific extractable nuclear antigens (ENAs) as diagnostic and prognostic tools and inducers of a profibrotic phenotype in cultured human skin fibroblasts: are they functional?"],"prefix":"10.1186","volume":"21","author":[{"given":"Claudio","family":"Corallo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cheleschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Cutolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Soldano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Fioravanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nila","family":"Volpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Franci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranuccio","family":"Nuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,24]]},"reference":[{"key":"1931_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7861\/clinmedicine.16-1-55","volume":"16","author":"CP Denton","year":"2016","unstructured":"Denton CP. Advances in pathogenesis and treatment of systemic sclerosis. Clin Med (Lond). 2016;16:55\u201360.","journal-title":"Clin Med (Lond)"},{"key":"1931_CR2","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1186\/ar1790","volume":"7","author":"VS Rajkumar","year":"2005","unstructured":"Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM, Abraham DJ. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther. 2005;7:1113\u201323.","journal-title":"Arthritis Res Ther."},{"key":"1931_CR3","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202\u20135.","journal-title":"J Rheumatol"},{"key":"1931_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.5301\/jsrd.5000216","volume":"1","author":"Y Allanore","year":"2016","unstructured":"Allanore Y. Limited cutaneous systemic sclerosis: the unfairly neglected subset. J Scleroderma Relat Disord. 2016;1:241\u20136.","journal-title":"J Scleroderma Relat Disord"},{"key":"1931_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.clindermatol.2018.04.004","volume":"36","author":"DR Pearson","year":"2018","unstructured":"Pearson DR, Werth VP, Pappas-Taffer L. Systemic sclerosis: current concepts of skin and systemic manifestations. Clin Dermatol. 2018;36:459\u201374.","journal-title":"Clin Dermatol"},{"key":"1931_CR6","doi-asserted-by":"publisher","unstructured":"Stochmal, A., Czuwara, J., Trojanowska, M. et al. Clinic Rev Allerg Immunol. 2019; \n                    https:\/\/doi.org\/10.1007\/s12016-018-8718-8\n                    \n                  .","DOI":"10.1007\/s12016-018-8718-8"},{"key":"1931_CR7","first-page":"9856910","volume":"2018","author":"FW Banhuk","year":"2018","unstructured":"Banhuk FW, Pahim BC, Jorge AS, Menolli RA. Relationships among antibodies against extractable nuclear antigens, antinuclear antibodies, and autoimmune diseases in a Brazilian public hospital. Autoimmune Dis. 2018;2018:9856910.","journal-title":"Autoimmune Dis"},{"key":"1931_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0889-857X(05)70297-0","volume":"22","author":"Y Okano","year":"1996","unstructured":"Okano Y. Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin N Am. 1996;22:709\u201335.","journal-title":"Rheum Dis Clin N Am"},{"key":"1931_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0065-2776(08)60641-0","volume":"44","author":"EM Tan","year":"1989","unstructured":"Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93\u2013151.","journal-title":"Adv Immunol"},{"key":"1931_CR10","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.clindermatol.2018.04.008","volume":"36","author":"DM Tartar","year":"2018","unstructured":"Tartar DM, Chung L, Fiorentino DF. Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis. Clin Dermatol. 2018;36:508\u201324.","journal-title":"Clin Dermatol"},{"key":"1931_CR11","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/BOR.0000000000000325","volume":"28","author":"MY Choi","year":"2016","unstructured":"Choi MY, Fritzler MJ. Progress in understanding the diagnostic and pathogenic role of autoantibodies associated with systemic sclerosis. Curr Opin Rheumatol. 2016;28:586\u201394.","journal-title":"Curr Opin Rheumatol"},{"key":"1931_CR12","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1080\/08916934.2017.1357699","volume":"50","author":"C Liaskos","year":"2017","unstructured":"Liaskos C, Marou E, Simopoulou T, Barmakoudi M, Efthymiou G, Scheper T, et al. Disease-related autoantibody profile in patients with systemic sclerosis. Autoimmunity. 2017;50:414\u201321.","journal-title":"Autoimmunity."},{"key":"1931_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1272\/jnms.84.56","volume":"84","author":"M Kuwana","year":"2017","unstructured":"Kuwana M. Circulating anti-nuclear antibodies in systemic sclerosis: utility in diagnosis and disease subsetting. J Nippon Med Sch. 2017;84:56\u201363.","journal-title":"J Nippon Med Sch"},{"issue":"4","key":"1931_CR14","first-page":"109","volume":"36 Suppl 113","author":"M Boonstra","year":"2018","unstructured":"Boonstra M, Mertens BJA, Bakker JA, Ninaber MK, Ajmone Marsan N, van der Helm-van Mil AHM, et al. To what extent do autoantibodies help to identify high-risk patients in systemic sclerosis? Clin Exp Rheumatol. 2018;36 Suppl 113(4):109\u201317.","journal-title":"Clin Exp Rheumatol"},{"key":"1931_CR15","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F Van den Hoogen","year":"2013","unstructured":"Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747\u201355.","journal-title":"Ann Rheum Dis"},{"key":"1931_CR16","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F Van den Hoogen","year":"2013","unstructured":"Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European league against rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737\u201347.","journal-title":"Arthritis Rheum"},{"key":"1931_CR17","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1002\/acr.22304","volume":"66","author":"G Valentini","year":"2014","unstructured":"Valentini G, Marcoccia A, Cuomo G, Vettori S, Iudici M, Bondanini F, et al. Early systemic sclerosis: analysis of the disease course in patients with marker autoantibody and\/or capillaroscopic positivity. Arthritis Care Res. 2014;66:1520\u20137.","journal-title":"Arthritis Care Res"},{"key":"1931_CR18","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.semarthrit.2014.11.006","volume":"44","author":"GA Salazar","year":"2015","unstructured":"Salazar GA, Assassi S, Wigley F, Hummers L, Varga J, Hinchcliff M, et al. Antinuclear antibody-negative systemic sclerosis. Semin Arthritis Rheum. 2015;44:680\u20136.","journal-title":"Semin Arthritis Rheum"},{"key":"1931_CR19","first-page":"OD12","volume":"10","author":"R Chander","year":"2016","unstructured":"Chander R, Singh S, Kalantri SA, Charan S, Gupta A. Sero-negative systemic sclerosis: a rare presentation. J Clin Diagn Res. 2016;10:OD12\u20133.","journal-title":"J Clin Diagn Res"},{"key":"1931_CR20","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/art.1780330828","volume":"33","author":"PJ Clements","year":"1990","unstructured":"Clements PJ, Lachenruch PA, Nq SC, Simmons M, Sterz M, Furst DE. Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum. 1990;33:1256\u201363.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1931_CR21","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.3390\/ijms19123909","volume":"19","author":"Sara Cheleschi","year":"2018","unstructured":"Cheleschi S, Giordano N, Volpi N, Tenti S, Gallo I, Di Meglio M, et al. A complex relationship between Visfatin and Resistin and microRNA: an in vitro study on human chondrocyte cultures. Int J Mol Sci. 2018;19:3909.","journal-title":"International Journal of Molecular Sciences"},{"key":"1931_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S0304-3940(02)01423-4","volume":"339","author":"C Ramakers","year":"2003","unstructured":"Ramakers C, Ruijter JM, Deprez RH, Moorman AF. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett. 2003;339:62\u20136.","journal-title":"Neurosci Lett"},{"key":"1931_CR23","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl MW. A new mathematical model for relative quantification in real RT-PCR. Nucleic Acid Res. 2001;29:e45.","journal-title":"Nucleic Acid Res"},{"key":"1931_CR24","doi-asserted-by":"publisher","first-page":"research0034.1","DOI":"10.1186\/gb-2002-3-7-research0034","volume":"3","author":"J Vandesompele","year":"2002","unstructured":"Vandesompele J, de Preter K, Pattyn F, Poppe B, van Roy N, de Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:research0034.1.","journal-title":"Genome Biol"},{"key":"1931_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/0394632015572750","volume":"28","author":"C Corallo","year":"2015","unstructured":"Corallo C, Franci B, Lucani B, Montella A, Chirico C, Gonnelli S, et al. From microvasculature to fibroblasts: contribution of anti-endothelial cell antibodies in systemic sclerosis. Int J Immunopathol Pharmacol. 2015;28:93\u2013103.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"1931_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3899\/jrheum.160736","volume":"44","author":"C Corallo","year":"2017","unstructured":"Corallo C, Santucci A, Bernardini G, Figura N, Leoncini R, Riolo G, et al. Proteomic investigation of dermal fibroblasts isolated from affected and unaffected skin samples from patients with limited cutaneous systemic sclerosis: 2 distinct entities? J Rheumatol. 2017;44:40\u20138.","journal-title":"J Rheumatol"},{"key":"1931_CR27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.autrev.2012.05.011","volume":"12","author":"S Mehra","year":"2013","unstructured":"Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev. 2013;12:340\u201354.","journal-title":"Autoimmun Rev"},{"key":"1931_CR28","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/rheumatology\/kew298","volume":"55","author":"P Kranenburg","year":"2016","unstructured":"Kranenburg P, van den Hombergh WM, Knaapen-Hans HK, van den Hoogen FH, Fransen J, Vonk MC. Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study. Rheumatology (Oxford). 2016;55:2001\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"1931_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","volume":"35","author":"VD Steen","year":"2005","unstructured":"Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35:35\u201342.","journal-title":"Semin Arthritis Rheum"},{"key":"1931_CR30","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","volume":"73","author":"JG Coghlan","year":"2014","unstructured":"Coghlan JG, Denton CP, Grunig E, Bonderman D, Distler O, Khanna D, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73:1340\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1931_CR31","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/rheumatology\/keg170","volume":"42","author":"R Hesselstrand","year":"2003","unstructured":"Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford). 2003;42:534\u201340.","journal-title":"Rheumatology (Oxford)"},{"key":"1931_CR32","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3389\/fimmu.2018.02452","volume":"9","author":"A van Caam","year":"2018","unstructured":"van Caam A, Vonk M, van den Hoogen F, van Lent P, van der Kraan P. Unraveling SSc pathophysiology; the Myofibroblast. Front Immunol. 2018;9:2452.","journal-title":"Front Immunol"},{"key":"1931_CR33","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.autrev.2018.06.009","volume":"17","author":"JPL Nunes","year":"2018","unstructured":"Nunes JPL, Cunha AC, Meirinhos T, Nunes A, Ara\u00fajo PM, Godinho AR, et al. Prevalence of auto-antibodies associated to pulmonary arterial hypertension in scleroderma - a review. Autoimmun Rev. 2018;17:1186\u2013201.","journal-title":"Autoimmun Rev"},{"key":"1931_CR34","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/art.23486","volume":"58","author":"D Kim","year":"2008","unstructured":"Kim D, Peck A, Santer D, Patole P, Schwartz SM, Molitor JA, et al. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum. 2008;58:2163\u201373.","journal-title":"Arthritis Rheum"},{"key":"1931_CR35","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.matbio.2018.01.025","volume":"69","author":"JN Schulz","year":"2018","unstructured":"Schulz JN, Plomann M, Sengle G, Gullberg D, Krieg T, Eckes B. New developments on skin fibrosis - essential signals emanating from the extracellular matrix for the control of myofibroblasts. Matrix Biol. 2018;69:522\u201332.","journal-title":"Matrix Biol"},{"key":"1931_CR36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.clinbiochem.2014.11.008","volume":"48","author":"K Ohyama","year":"2015","unstructured":"Ohyama K, Baba M, Tamai M, Aibara N, Ichinose K, Kishikawa N, et al. Proteomic profiling of antigens in circulating immune complexes associated with each of seven autoimmune diseases. Clin Biochem. 2015;48:181\u20135.","journal-title":"Clin Biochem"},{"key":"1931_CR37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13075-018-1689-6","volume":"20","author":"E Raschi","year":"2018","unstructured":"Raschi E, Chighizola CB, Cesana L, Privitera D, Ingegnoli F, Mastaglio C, et al. Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts. Arthritis Res Ther. 2018;20:187.","journal-title":"Arthritis Res Ther"},{"key":"1931_CR38","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/art.21646","volume":"54","author":"J H\u00e9nault","year":"2006","unstructured":"H\u00e9nault J, Robitaille G, Sen\u00e9cal JL, Raymond Y. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum. 2006;54:963\u201373.","journal-title":"Arthritis Rheum"},{"key":"1931_CR39","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1002\/art.20515","volume":"50","author":"J H\u00e9nault","year":"2004","unstructured":"H\u00e9nault J, Tremblay M, Cl\u00e9ment I, Raymond Y, Sen\u00e9cal JL. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. Arthritis Rheum. 2004;50:3265\u201374.","journal-title":"Arthritis Rheum"},{"key":"1931_CR40","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/jcb.25654","volume":"118","author":"A Girstun","year":"2017","unstructured":"Girstun A, Ishikawa T, Kowalska-Loth B, Czubaty A, Staron K. Subnuclear localization of human topoisomerase I. J Cell Biochem. 2017;118:407\u201319.","journal-title":"J Cell Biochem"},{"key":"1931_CR41","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1189\/jlb.1004623","volume":"77","author":"JJ Oppenheim","year":"2005","unstructured":"Oppenheim JJ, Dong HF, Plotz P, Caspi RR, Dykstra M, Pierce S, et al. Autoantigens act as tissue-specific chemoattractants. J Leukoc Biol. 2005;77:854\u201361.","journal-title":"J Leukoc Biol"},{"key":"1931_CR42","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1002\/art.22972","volume":"56","author":"G Robitaille","year":"2007","unstructured":"Robitaille G, Henault J, Christin MS, Senecal JL, Raymond Y. The nuclear autoantigen CENP-B displays cytokine-like activities toward vascular smooth muscle cells. Arthritis Rheum. 2007;56:3814\u201326.","journal-title":"Arthritis Rheum"},{"key":"1931_CR43","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1002\/art.24765","volume":"60","author":"G Robitaille","year":"2009","unstructured":"Robitaille G, Christin MS, Clement I, Senecal JL, Raymond Y. Nuclear autoantigen CENP-B transactivation of the epidermal growth factor receptor via chemokine receptor 3 in vascular smooth muscle cells. Arthritis Rheum. 2009;60:2805\u201316.","journal-title":"Arthritis Rheum"},{"key":"1931_CR44","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/01.bor.0000245728.40630.27","volume":"18","author":"OZ Howard","year":"2006","unstructured":"Howard OZ. Autoantigen signalling through chemokine receptors. Curr Opin Rheumatol. 2006;18:642\u20136.","journal-title":"Curr Opin Rheumatol"},{"key":"1931_CR45","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.berh.2018.08.005","volume":"32","author":"F Ingegnoli","year":"2018","unstructured":"Ingegnoli F, Ughi N, Mihai C. Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis. Best Pract Res Clin Rheumatol. 2018;32:223\u201340.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"Suppl 113","key":"1931_CR46","first-page":"3","volume":"36","author":"M Orlandi","year":"2018","unstructured":"Orlandi M, Barsotti S, Lepri G, Codullo V, Di Battista M, Guiducci S, et al. One year in review 2018: systemic sclerosis. Clin Exp Rheumatol. 2018;36(Suppl 113):3\u201323.","journal-title":"Clin Exp Rheumatol"},{"key":"1931_CR47","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1749-6632.1996.tb26405.x","volume":"803","author":"L Rudnicka","year":"1996","unstructured":"Rudnicka L, Czuwara J, Barusi\u0144ska A, Nowicka U, Makie\u0142a B, Jab\u0142onska S. Implications for the use of topoisomerase I inhibitors in treatment of patients with systemic sclerosis. Ann N Y Acad Sci. 1996;803:318\u201320.","journal-title":"Ann N Y Acad Sci"},{"key":"1931_CR48","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00281-015-0513-5","volume":"37","author":"J G\u00fcnther","year":"2015","unstructured":"G\u00fcnther J, Rademacher J, van Laar JM, Siegert E, Riemekasten G. Functional autoantibodies in systemic sclerosis. Semin Immunopathol. 2015;37:529\u201342.","journal-title":"Semin Immunopathol"},{"issue":"2","key":"1931_CR49","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1136\/ard.2008.102400","volume":"69","author":"C Mihai","year":"2010","unstructured":"Mihai C, Tervaert JW. Anti-endothelial cell antibodies in systemic sclerosis. Ann Rheum Dis. 2010;69(2):319\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1931_CR50","first-page":"173","volume":"18","author":"P Vahidi Manesh","year":"2019","unstructured":"Vahidi Manesh P, Farazmand A, Gharibdoost F, Vanaki N, Mostafaei S, Kavosi H, et al. Downregulation of miR-542-3p contributes to apoptosis resistance in dermal fibroblasts from systemic sclerosis patients via Survivin overexpression. Iran J Allergy Asthma Immunol. 2019;18(2):173\u201381.","journal-title":"Iran J Allergy Asthma Immunol"},{"issue":"420","key":"1931_CR51","doi-asserted-by":"publisher","first-page":"eaal3765","DOI":"10.1126\/scitranslmed.aal3765","volume":"9","author":"D Lagares","year":"2017","unstructured":"Lagares D, Santos A, Grasberger PE, Liu F, Probst CK, Rahimi RA, et al. Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis. Sci Transl Med. 2017;9(420):eaal3765.","journal-title":"Sci Transl Med"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1931-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1931-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1931-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T19:36:19Z","timestamp":1592854579000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1931-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,24]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1931"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1931-x","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,24]]},"assertion":[{"value":"18 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients gave their fully informed, voluntary, and written consent according to the principles of the Declaration of Helsinki and in compliance with the ethics committee of the University of Siena, whose institutional review board approved the entire study protocol.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}